Evidence map›Paper›PMID 24227810›Full record

ReviewEuropean heart journal2014

Natriuretic peptides in cardiovascular diseases: current use and perspectives.

Massimo Volpe, Speranza Rubattu, John Burnett

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 1 synthesis or guideline pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. NT-proBNP in the very old population: reference values and heart failure specificity from the AugUR-study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Massimo VolpeDepartment of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University of Rome, Ospedale S. Andrea, Rome, Italy.
Speranza Rubattu
John Burnett
Azienda Ospedaliera Sant'Andrea · ITMayo Clinic · USSapienza University of Rome · IT

Funding

INTRARENAL REGULATION OF SODIUM EXCRETIONR01HL036634 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C · 1987 to 2019
$6.5M
Cardiovascular Peptides and Myocardial InfarctionR01HL083231 · NHLBI · MAYO CLINIC ROCHESTER · PI BURNETT, JOHN C, CHEN, HORNG H · 2006 to 2016
$4.6M
NHLBI NIH HHS R01 HL036634NHLBI NIH HHS R01 HL083231
6 · The paper itself

Abstract

The natriuretic peptides (NPs) family, including atrial, B-type, and C-type NPs, is a group of hormones possessing relevant haemodynamic and anti-remodelling actions in the cardiovascular (CV) system. Due to their diuretic, natriuretic, vasorelaxant, anti-proliferative, and anti-hypertrophic effects, they are involved in the pathogenic mechanisms leading to major CV diseases, such as heart failure (HF), coronary artery disease, hypertension and left ventricular hypertrophy, and cerebrovascular accidents. Blood levels of NPs have established predictive value in the diagnosis of HF, as well as for its prognostic stratification. In addition, they provide useful clinical information in hypertension and in both stable and unstable coronary artery disease. Structural abnormalities of atrial natriuretic peptide gene (NPPA), as well as genetically induced changes in circulating levels of NPs, have a pathogenic causal link with CV diseases and represent emerging markers of CV risk. Novel NP-based therapeutic strategies are currently under advanced clinical development, as they are expected to contribute to the future management of hypertension and HF. The present review provides a current appraisal of NPs' clinical implications and a critical perspective of the potential therapeutic impact of pharmacological manipulation of this class of CV hormones.

Indexed as

Cardiovascular DiseasesHumansNatriuretic PeptidesPractice Guidelines as TopicPrognosisRenin-Angiotensin SystemRisk AssessmentNatriuretic PeptidesARNiCardiovascular diseasesGeneticsNatriuretic peptidesNatriuretic peptides analoguesNEP inhibitors

Identifiers

PMID24227810
PMCPMC4023301
OpenAlexW2157574602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.